Recent advances in DDR (DNA damage response) inhibitors for cancer therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy
Authors
Keywords
DNA damage Response, Synthetic lethality, Small molecule inhibitors
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 230, Issue -, Pages 114109
Publisher
Elsevier BV
Online
2022-01-13
DOI
10.1016/j.ejmech.2022.114109
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer
- (2021) Seung Tae Kim et al. CLINICAL CANCER RESEARCH
- GDC-0575, a CHK1 Inhibitor, Impairs the Development of Colitis and Colitis-Associated Cancer by Inhibiting CCR2+ Macrophage Infiltration in Mice
- (2021) Min Li et al. OncoTargets and Therapy
- Discovery of Novel Apigenin–Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer
- (2021) Huan Long et al. JOURNAL OF MEDICINAL CHEMISTRY
- PARP and PARG inhibitors in cancer treatment
- (2020) Dea Slade GENES & DEVELOPMENT
- Targeting DNA-PK in cancer
- (2020) Giovanna Damia MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy
- (2020) Lukas Gorecki et al. PHARMACOLOGY & THERAPEUTICS
- Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
- (2020) Stephen A. Jannetti et al. Frontiers in Pharmacology
- Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
- (2020) José Yélamos et al. Cancers
- PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
- (2020) Ahrum Min et al. Cancers
- Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma
- (2020) Linsong Tang et al. CANCER LETTERS
- Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer
- (2020) Biagio Ricciuti et al. CLINICAL CANCER RESEARCH
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
- (2020) Frank T. Zenke et al. MOLECULAR CANCER THERAPEUTICS
- Biomarker-Guided Development of DNA Repair Inhibitors
- (2020) James M. Cleary et al. MOLECULAR CELL
- Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
- (2020) Catherine Hanna et al. NEURO-ONCOLOGY
- Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer
- (2020) Yunlong Hu et al. CANCER SCIENCE
- Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
- (2020) Ulrich Lücking et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-activity relationships of Wee1 inhibitors: A review
- (2020) Xingkai Du et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
- (2020) Timothy A. Yap et al. Cancer Discovery
- PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
- (2020) Maddison Rose et al. Frontiers in Cell and Developmental Biology
- Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010-present)
- (2020) Suwen Hu et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Rucaparib: A Review in Ovarian Cancer
- (2019) Matt Shirley Targeted Oncology
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer
- (2019) Paul Dent EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
- (2019) Stergios Boussios et al. INVESTIGATIONAL NEW DRUGS
- The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models
- (2019) Antje M. Wengner et al. MOLECULAR CANCER THERAPEUTICS
- Synthetic lethality as an engine for cancer drug target discovery
- (2019) Alan Huang et al. NATURE REVIEWS DRUG DISCOVERY
- AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
- (2019) Jacqueline H. L. Fok et al. Nature Communications
- WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer
- (2019) Andrea Sand et al. CANCER LETTERS
- Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib
- (2019) Christopher L. Heidler et al. INTERNATIONAL JOURNAL OF CANCER
- The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor
- (2019) Frederick W. Goldberg et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
- (2018) A Italiano et al. ANNALS OF ONCOLOGY
- PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
- (2018) Dalia Kamel et al. CURRENT DRUG TARGETS
- Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
- (2018) Anish Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors
- (2018) Bin Yang et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)
- (2018) Kurt G. Pike et al. JOURNAL OF MEDICINAL CHEMISTRY
- The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells GrownIn Vitroand as Orthotopic Xenografts
- (2018) Cindy R. Timme et al. MOLECULAR CANCER THERAPEUTICS
- The comings and goings of PARP-1 in response to DNA damage
- (2018) John M. Pascal DNA REPAIR
- Niraparib: A Review in Ovarian Cancer
- (2018) Young-A Heo et al. Targeted Oncology
- Talazoparib: First Global Approval
- (2018) Sheridan M. Hoy DRUGS
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Directing the use of DDR kinase inhibitors in cancer treatment
- (2017) Inger Brandsma et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
- (2017) Ahrum Min et al. MOLECULAR CANCER THERAPEUTICS
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
- (2017) Andrew N. Blackford et al. MOLECULAR CELL
- Synthetic lethality screens point the way to new cancer drug targets
- (2017) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Synthetic lethality and cancer
- (2017) Nigel J. O'Neil et al. NATURE REVIEWS GENETICS
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Translational research in radiation-induced DNA damage signaling and repair
- (2017) Jac A. Nickoloff et al. Translational Cancer Research
- Targeting the ATR-CHK1 Axis in Cancer Therapy
- (2017) Stuart Rundle et al. Cancers
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
- (2016) S. Percy Ivy et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy
- (2016) Ying-Qing Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting WEE1 Kinase in Cancer
- (2016) Christopher J. Matheson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Kinase hinge binding scaffolds and their hydrogen bond patterns
- (2015) Li Xing et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain
- (2015) Jennine M. Dawicki-McKenna et al. MOLECULAR CELL
- DDR-mediated crosstalk between DNA-damaged cells and their microenvironment
- (2015) Nicolas Malaquin et al. Frontiers in Genetics
- Beyond DNA Repair: DNA-PK Function in Cancer
- (2014) J. F. Goodwin et al. Cancer Discovery
- Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone
- (2014) Mika Aoyagi-Scharber et al. Acta Crystallographica Section F-Structural Biology Communications
- Roles of Chk1 in cell biology and cancer therapy
- (2013) Youwei Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Targeting the DNA damage response in oncology
- (2012) Bristi Basu et al. CURRENT OPINION IN ONCOLOGY
- Unleashing Chk1 in cancer therapy
- (2011) Laura Carrassa et al. CELL CYCLE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started